Citizens Highlights Summit’s (SMMT) Ivonescimab Superiority, Reiterates at Outperform
Tweet Send to a Friend
(Updated - October 20, 2025 9:50 AM EDT)
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
